Vector Laboratories, a company involved in innovative proteomic and glycomic research solutions, acquired Quanta BioDesign, the inventor of discrete polyethylene glycol (dPEG) technology for advanced bioconjugate and payload delivery design for life science and biopharma applications. The acquisition further expands Vector Laboratories’ portfolio of bioconjugation linkers and dyes and builds on its manufacturing and bioconjugation capabilities to better serve partners across biopharma and the life sciences.

Quanta BioDesign develops patented and innovative cross-linking and labeling chemistries that incorporate and are uniquely enabled by its dPEG technology, allowing for new approaches in the areas of therapeutic and diagnostic development.

“This acquisition is valuable because it supports Vector Laboratories’ long-term strategic vision of accelerating the pace of scientific discovery for life science companies and transformational treatments and approaches for biopharma companies,” said Lisa Sellers, CEO of Vector Laboratories. “It also builds on our recent acquisition of Click Chemistry Tools and Fluoroprobes and goes beyond standard linker capabilities to serve broader industrial segments, expanding what’s possible for customers in manufacturing components for their end products. We can now offer a breadth of options to provide the best solution for our customers’ challenges.”

Vector Laboratories acquired Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling reagents, and Fluoroprobes, a leader in fluorescent probes and dyes earlier this year. In addition, Vector Laboratories was the first company to commercialize avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence. The company has introduced over 600 reliable reagents and kits through four decades of leadership in labeling and detection technologies.